Dr. Angelos M. Stergiou, MD, ScD h.c. founded SELLAS Life Sciences Group with Dr. Miltos K. Sugiultzoglu, a friend and colleague.
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
About SELLAS Life Sciences Group
Dr. Angelos M. Stergiou, MD, ScD h.c. is the CEO and Vice Chairman
of SELLAS Life Sciences Group, which he founded with the intention
to give back to humanity through clinical research, discovery and
In recent news, Dr. Angelos Stergiou and SELLAS Life Sciences
Group have received increasing media coverage as the progression
of the WT1 neoepitome immunotherapeutic anti-cancer treatment
and vaccine continues to yield promising results.
The points below will help you learn more about SELLAS Life
Sciences Group and what the company is contributing to the world:
SELLAS Life Sciences Group. As a leading international
biopharmaceutical company, SELLAS Life Sciences focuses on
advancing various cancer therapies and developing diverse
cancer programs. The company seeks to improve the lives of
patients everywhere by commercializing cutting-edge cancer
WT1 Neoepitope Immunotherapy. Named for the WT1 antigen –
one of the most common antigens found in malignancies – the
WT1 anti-cancer treatment, called galinpepimut-S, consists of
four synthetically heteroclitically modified peptide chains that
are designed to induce patient immune response against the
WT1 antigen. As of 2016, trial phases have shown promising
To learn more about the work of SELLAS Life Sciences Group or Dr.
Angelos Stergiou, visit www.sellaslifesciences.com
Also connected with Angelos Stergiou through social profiles: